Contrasting Mymd Pharmaceuticals (QCLS) & Its Competitors

Mymd Pharmaceuticals (NASDAQ:QCLS) is one of 82 public companies in the “Technology Hardware, Storage & Peripherals” industry, but how does it weigh in compared to its peers? We will compare Mymd Pharmaceuticals to related companies based on the strength of its institutional ownership, dividends, profitability, valuation, analyst recommendations, earnings and risk.

Risk and Volatility

Mymd Pharmaceuticals has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Mymd Pharmaceuticals’ peers have a beta of 1.56, suggesting that their average stock price is 56% more volatile than the S&P 500.

Profitability

This table compares Mymd Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
Mymd Pharmaceuticals Competitors	-639.13%	-14.37%	2.86%

Insider and Institutional Ownership

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. Comparatively, 51.3% of shares of all “Technology Hardware, Storage & Peripherals” companies are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Comparatively, 10.5% of shares of all “Technology Hardware, Storage & Peripherals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Mymd Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	-$11.63 million	-0.14
Mymd Pharmaceuticals Competitors	$23.51 billion	$3.24 billion	13.37

Mymd Pharmaceuticals’ peers have higher revenue and earnings than Mymd Pharmaceuticals. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Mymd Pharmaceuticals and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1	0	0	0	1.00
Mymd Pharmaceuticals Competitors	1047	4266	7596	357	2.55

As a group, “Technology Hardware, Storage & Peripherals” companies have a potential upside of 25.81%. Given Mymd Pharmaceuticals’ peers stronger consensus rating and higher possible upside, analysts clearly believe Mymd Pharmaceuticals has less favorable growth aspects than its peers.

Summary

Mymd Pharmaceuticals peers beat Mymd Pharmaceuticals on 11 of the 13 factors compared.

Mymd Pharmaceuticals Company Profile

TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.